Surrozen, Inc. Files 2025 Annual Report: Key Developments, Financial Position, and Risks for Investors

Executive Summary

Surrozen, Inc. (Nasdaq: SRZN) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains critical information about the company’s financial performance, risk factors, governance, and forward-looking statements. This comprehensive analysis will cover the major highlights, essential details for shareholders, and potential market-moving developments.

Key Points from the Annual Report

• Fiscal Year End: December 31, 2025
• Common Stock Information: Surrozen’s common stock is traded on the Nasdaq Capital Market under the symbol SRZN.
• Public Float: The aggregate market value of voting stock held by non-affiliates as of June 30, 2025, was approximately \$59.7 million, based on a closing price of \$8.94 per share.
• Shares Outstanding: 11,486,707 shares of common stock as of the filing date.
• Annual Meeting: Portions of the next proxy statement will be incorporated by reference into Part III of the 10-K.
• Registrant Status: Surrozen is a “smaller reporting company” and is not a well-known seasoned issuer or an emerging growth company.
• Compliance: The company has filed all required reports for the past 12 months and is subject to the Exchange Act’s filing requirements.
• Controls & Procedures: No auditor attestation of internal control over financial reporting was required.

Potentially Price-Sensitive Information for Shareholders

• Forward-Looking Statements and Risks:
  Surrozen’s management highlights a number of uncertainties that could materially impact future performance, including:
  • Ability to develop and expand drug discovery and development capabilities
  • Funding requirements for ongoing clinical trials and product development
  • Risks related to identifying, developing, and commercializing product candidates
  • Competition from other products that may receive regulatory approval sooner
  • Personnel changes and the availability of qualified employees
  • Ability to manage rapid growth and expansion
  • Macroeconomic risks, including market volatility, tariffs, and global events
  • Concentration of share ownership among a few large holders, which could impact voting outcomes and governance
  • Increasingly competitive environment

  The company explicitly warns that these risks may affect its ability to deliver future returns, and that forward-looking statements are not guarantees of future performance. Investors should not place undue reliance on these statements.

• Regulatory and Reporting Status:
  Surrozen is not an emerging growth company and does not benefit from extended transition periods for new accounting standards. There have been no restatements or corrections of previous financial statements requiring recovery analysis of executive compensation.
• Auditor Attestation:
  The company’s internal control over financial reporting has not been subject to auditor attestation, which may be noteworthy for some institutional investors.
• No Indication of Being a Shell Company:
  Surrozen confirms it is not a shell company, which is important for its eligibility to participate in certain capital markets activities.

Corporate Governance and Shareholder Information

• Securities Registered:
  • Common Stock, \$0.0001 par value per share (Nasdaq: SRZN)
  • Redeemable warrants (Nasdaq: SRZNW), each whole warrant exercisable for one-fifteenth of a share of common stock
• Sections in the Annual Report:
  The 10-K contains detailed sections on Business, Risk Factors, Management’s Discussion and Analysis, Financial Statements, and Corporate Governance (directors, executive officers, compensation, ownership, related transactions, principal accounting fees, and more).
• Proxy Statement Reference:
  The 2026 Annual Meeting Proxy Statement will be filed within 120 days and referenced for certain governance matters.

Summary Table of Contents

The report includes key sections such as:

• Business Overview
• Risk Factors
• Mine Safety Disclosures
• Market for Common Equity and Related Stockholder Matters
• Management’s Discussion and Analysis of Financial Condition and Results of Operations
• Quantitative and Qualitative Disclosures About Market Risk
• Financial Statements and Supplementary Data
• Changes in and Disagreements with Accountants
• Directors, Executive Officers, Corporate Governance, and Compensation
• Security Ownership and Related Stockholder Matters
• Certain Relationships and Related Transactions
• Principal Accounting Fees and Services
• Exhibits and Financial Statement Schedules
• Form 10-K Summary

Conclusion for Investors

Key investor takeaway: Surrozen, Inc.’s 2025 Annual Report provides a comprehensive look at the company’s financial and operational status, including its public float, reporting compliance, and risk landscape. The company’s warnings regarding funding needs, competition, macroeconomic risks, and concentrated ownership are material considerations for investors. There are no signs of financial restatements or shell company status, which is reassuring. The absence of auditor attestation for internal controls may be a point of focus for some institutional investors. Overall, the company remains compliant and continues to pursue its drug development pipeline in an increasingly competitive and volatile environment.

Disclaimer: This article is a summary and analysis of Surrozen, Inc.’s SEC 10-K filing for 2025 based solely on the information contained in the report. It does not constitute investment advice. Investors should review the full filing and consult their financial advisors before making investment decisions. Surrozen’s forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those described.

View Surrozen, Inc./DE Historical chart here